Conduct Bioequivalence Study: CDSCO panel tells Abbott India on Dydrogesterone MR Tablets
New Delhi: Responding to the proposal for manufacturing and marketing synthetic progesterone, Dydrogesterone Modified-release (MR) Tablets presented by Abbott India, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has recommended the firm to conduct the bioequivalence (BE) study as per the protocol and submit the report along with the clinical trial protocol.
This came after the drug major Abbott India presented the proposal for manufacturing and marketing of Dydrogesterone MR tablet 30 mg along with BE study protocol and clinical trial protocol before the committee.
Dydrogesterone is a synthetic progesterone for menstrual cycle regulation, infertility treatment, prevention of miscarriage, and other conditions.
It is used to treat irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency and also used to prevent natural abortion in patients who have a history of habitual abortions.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.